Tandem Diabetes Care (TNDM) Net Equity Issued and Repurchased (2013 - 2024)

Tandem Diabetes Care's Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $2.3 million for Q4 2024.

• Quarterly Net Equity Issued and Repurchased fell 12.04% year-over-year to $2.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$6.7 million (down 260.85% YoY) and the FY2024 annual result came in at -$6.7 million, down 260.85% from the prior year.
• Net Equity Issued and Repurchased was $2.3 million for Q4 2024 at Tandem Diabetes Care, up from -$4.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $29.0 million in Q3 2020 and bottomed at -$4.5 million in Q3 2024.
• A 5-year average of $6.7 million and a median of $3.7 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased surged 504.53% — and 2023, when it slumped 398.64%.
• Tandem Diabetes Care's Net Equity Issued and Repurchased stood at $9.2 million in 2020, then surged by 72.89% to $15.9 million in 2021, then sank by 61.6% to $6.1 million in 2022, then tumbled by 57.1% to $2.6 million in 2023, then slipped by 12.04% to $2.3 million in 2024.
• Business Quant data shows TNDM's Net Equity Issued and Repurchased at $2.3 million in Q4 2024, -$4.5 million in Q3 2024, and -$3.0 million in Q2 2024.